Copanlisib 60 mg /vial Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 60 mg /vial

Reference Brands: Aliqopa (USA/EU)

Category: Oncology Cancer Care

Copanlisib is a phosphoinositide 3-kinase (PI3K) inhibitor used for the treatment of relapsed follicular lymphoma in adults who have received at least two prior systemic therapies. It works by blocking PI3K signaling, which helps slow the growth of cancer cells. The drug is administered as an intravenous infusion using a lyophilized powder formulation (60 mg per vial).

Product Description:

Copanlisib inhibits phosphoinositide 3-kinase, with activity concentrated on the alpha and delta isoforms. The delta isoform drives survival signalling in malignant B cells; the alpha isoform contributes an antiangiogenic effect. What distinguishes it from the oral drugs in the same class is the route: it is given as a short intravenous infusion on an intermittent schedule, which produces high peak exposure with drug-free intervals and was intended to avoid the cumulative immune toxicity that limits continuous oral dosing.

It is used for relapsed follicular lymphoma in adults after at least two prior systemic therapies. Because PI3K-alpha inhibition interferes with insulin signalling, transient hyperglycaemia occurs in most patients within hours of infusion and must be anticipated in diabetics. Hypertension follows the same pattern. Other risks include infusion-related reactions, non-infectious pneumonitis, severe neutropenia and opportunistic infection, with Pneumocystis prophylaxis recommended.

Sourcing notes. Originator product supplied as a 60 mg lyophilised powder for reconstitution. Its commercial position has narrowed since confirmatory trial data prompted regulatory reassessment of the PI3K class, so registration status should be verified market by market before committing. Cytotoxic handling and cold chain storage.